Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Eudocia Quant Lee, M.D.

Co-Author

This page shows the publications co-authored by Eudocia Lee and Ugonma Chukwueke.
Connection Strength

0.771
  1. Barriers to accrual and enrollment in brain tumor trials. Neuro Oncol. 2019 09 06; 21(9):1100-1117.
    View in: PubMed
    Score: 0.214
  2. Phase II trial of ponatinib in patients with bevacizumab-refractory glioblastoma. Cancer Med. 2019 10; 8(13):5988-5994.
    View in: PubMed
    Score: 0.214
  3. Phase II study of ipilimumab and nivolumab in leptomeningeal carcinomatosis. Nat Commun. 2021 10 12; 12(1):5954.
    View in: PubMed
    Score: 0.062
  4. Activity of PD-1 blockade with Nivolumab among patients with recurrent atypical/anaplastic meningioma: Phase II trial results. Neuro Oncol. 2021 May 20.
    View in: PubMed
    Score: 0.060
  5. Publisher Correction: Single-arm, open-label phase 2 trial of pembrolizumab in patients with leptomeningeal carcinomatosis. Nat Med. 2020 Aug; 26(8):1309.
    View in: PubMed
    Score: 0.057
  6. Single-arm, open-label phase 2 trial of pembrolizumab in patients with leptomeningeal carcinomatosis. Nat Med. 2020 08; 26(8):1280-1284.
    View in: PubMed
    Score: 0.056
  7. Integration of rare cell capture technology into cytologic evaluation of cerebrospinal fluid specimens from patients with solid tumors and suspected leptomeningeal metastasis. J Am Soc Cytopathol. 2020 Jan - Feb; 9(1):45-54.
    View in: PubMed
    Score: 0.054
  8. Letter: When Less is More: Dexamethasone Dosing for Brain Tumors. Neurosurgery. 2019 09 01; 85(3):E607-E608.
    View in: PubMed
    Score: 0.054
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.